Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 18 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-0.91 Insider Own14.36% Shs Outstand35.17M Perf Week-2.43%
Market Cap624.46M Forward P/E29.25 EPS next Y0.60 Insider Trans3.65% Shs Float30.30M Perf Month5.31%
Income-31.33M PEG- EPS next Q-0.18 Inst Own58.21% Short Float14.14% Perf Quarter65.73%
Sales138.68M P/S4.50 EPS this Y28.33% Inst Trans-4.54% Short Ratio7.99 Perf Half Y86.18%
Book/sh1.70 P/B10.39 EPS next Y212.25% ROA-12.23% Short Interest4.28M Perf Year-5.51%
Cash/sh2.15 P/C8.22 EPS next 5Y15.00% ROE-76.44% 52W Range7.60 - 22.63 Perf YTD57.59%
Dividend Est.- P/FCF98.03 EPS past 5Y- ROI-12.49% 52W High-22.01% Beta0.75
Dividend TTM- Quick Ratio2.73 Sales past 5Y27.34% Gross Margin69.77% 52W Low132.24% ATR (14)0.94
Dividend Ex-Date- Current Ratio2.99 EPS Y/Y TTM-40.50% Oper. Margin-5.28% RSI (14)60.67 Volatility5.82% 5.29%
Employees315 Debt/Eq3.19 Sales Y/Y TTM49.79% Profit Margin-22.59% Recom1.00 Target Price28.15
Option/ShortYes / Yes LT Debt/Eq3.18 EPS Q/Q-74.37% Payout- Rel Volume0.33 Prev Close17.69
Sales Surprise-4.77% EPS Surprise-74.71% Sales Q/Q32.50% EarningsMay 13 AMC Avg Volume536.41K Price17.65
SMA20-0.35% SMA5023.95% SMA20041.98% Trades Volume178,454 Change-0.23%
Date Action Analyst Rating Change Price Target Change
Apr-11-24Initiated Craig Hallum Buy $24
Sep-08-22Resumed B. Riley Securities Buy $17
Oct-14-21Resumed B. Riley Securities Buy $16
Sep-24-21Initiated Aegis Capital Buy $15
Jul-02-21Initiated Ladenburg Thalmann Buy $14.25
Jun-07-24 06:30AM
Jun-06-24 08:00AM
Jun-05-24 07:00AM
May-15-24 07:00AM
May-13-24 08:55PM
04:25PM Loading…
Apr-25-24 07:00AM
Apr-02-24 08:16AM
Mar-21-24 09:55AM
Mar-19-24 09:52PM
Mar-13-24 06:35AM
07:00AM Loading…
Mar-05-24 07:00AM
Mar-04-24 08:28PM
Feb-21-24 06:47AM
Feb-15-24 04:01PM
Jan-29-24 07:00AM
Jan-11-24 07:00AM
Jan-03-24 07:15AM
Dec-24-23 01:08PM
Nov-29-23 07:00AM
Nov-20-23 07:00AM
Nov-14-23 12:56PM
Nov-13-23 05:07PM
Oct-30-23 08:00AM
07:00AM Loading…
Oct-24-23 07:00AM
Sep-29-23 08:00AM
Sep-26-23 08:00AM
Sep-21-23 01:03PM
Aug-11-23 01:05PM
Aug-10-23 09:54AM
Aug-09-23 04:14PM
Jul-31-23 07:00AM
Jul-28-23 02:56PM
Jul-26-23 03:42PM
Jul-20-23 10:29AM
Jul-19-23 12:17PM
Jul-18-23 05:00PM
Jul-05-23 06:15PM
Jun-29-23 06:15PM
Jun-23-23 06:15PM
Jun-16-23 06:00PM
May-17-23 08:00AM
May-16-23 11:57AM
May-15-23 11:21AM
May-12-23 01:48PM
May-11-23 05:15PM
May-08-23 12:07PM
May-04-23 08:00AM
May-03-23 06:44AM
May-02-23 04:42PM
May-01-23 08:50AM
Apr-28-23 06:00PM
Apr-27-23 08:05AM
Apr-24-23 08:43AM
Apr-20-23 08:31AM
Apr-19-23 06:15PM
Apr-18-23 06:24AM
Apr-14-23 08:50AM
Apr-13-23 06:15PM
Apr-12-23 09:40AM
Apr-09-23 04:04PM
Apr-05-23 09:34AM
Apr-04-23 05:37AM
Apr-03-23 06:53AM
Mar-29-23 08:50AM
Mar-28-23 02:59PM
Mar-27-23 08:51AM
Mar-24-23 05:42AM
Mar-23-23 04:06PM
Mar-13-23 07:00AM
Mar-06-23 08:00AM
Mar-02-23 08:00AM
Feb-16-23 06:42AM
Feb-15-23 07:00AM
Feb-03-23 08:50AM
Feb-02-23 06:30AM
Jan-23-23 07:00AM
Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Opaleye Management Inc.10% OwnerApr 25 '24Buy9.9720,000199,4003,815,000Apr 25 05:19 PM
Opaleye Management Inc.10% OwnerApr 24 '24Buy10.158,28584,0933,795,000Apr 24 04:40 PM
Opaleye Management Inc.10% OwnerApr 23 '24Buy10.2911,715120,5473,786,715Apr 24 04:40 PM
Opaleye Management Inc.10% OwnerApr 19 '24Buy10.5629,400310,3903,775,000Apr 19 06:24 PM
Opaleye Management Inc.10% OwnerMar 28 '24Buy12.8250,000641,0003,745,600Mar 28 06:07 PM
BAUM MARK LCHIEF EXECUTIVE OFFICERMar 22 '24Buy11.599,000104,3102,137,525Mar 25 07:00 AM
Opaleye Management Inc.10% OwnerMar 20 '24Buy9.6550,600488,2903,695,600Mar 22 11:52 AM
SAHAREK JOHN P.CEO of ImprimisRxMar 01 '24Option Exercise8.755,00043,750254,803Mar 06 06:06 AM
BAUM MARK LCHIEF EXECUTIVE OFFICERFeb 20 '24Option Exercise10.67150,0001,600,5002,188,361Feb 21 07:29 PM
BOLL ANDREW R.CHIEF FINANCIAL OFFICERFeb 20 '24Option Exercise10.6745,000480,150586,569Feb 21 07:29 PM
SAHAREK JOHN P.CEO of ImprimisRxFeb 20 '24Option Exercise10.6730,000320,100262,419Feb 21 07:30 PM
BAUM MARK LCHIEF EXECUTIVE OFFICERFeb 07 '24Option Exercise7.7115,400118,7342,038,361Feb 08 07:30 AM
BOLL ANDREW R.CHIEF FINANCIAL OFFICERFeb 07 '24Option Exercise7.717,40057,054541,569Feb 08 07:30 AM
BAUM MARK LChief Executive OfficerNov 16 '23Buy8.117,50060,8252,022,961Nov 16 04:45 PM
Opaleye Management Inc.10% OwnerNov 15 '23Buy8.0325,000200,7353,645,000Nov 16 04:05 PM
Opaleye Management Inc.10% OwnerSep 20 '23Buy14.495,98386,7103,620,000Sep 20 06:39 PM
Opaleye Management Inc.10% OwnerSep 19 '23Buy14.6514,017205,3663,614,017Sep 20 06:39 PM
Makary Martin A.DirectorAug 14 '23Buy16.9220,000338,40045,000Aug 15 07:30 AM
BAUM MARK LChief Executive OfficerAug 14 '23Buy17.055,80098,8902,015,461Aug 15 07:30 AM